Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
19.54
-0.87 (-4.26%)
At close: Nov 11, 2026, 4:00 PM EST
19.30
-0.24 (-1.23%)
After-hours: Nov 11, 2026, 5:37 PM EST
Legend Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,359 | 1,029 | 627.3 | 285.1 | 116.68 | 65.4 |
Other Revenue | - | - | - | - | 0.33 | 3.42 |
| 1,359 | 1,029 | 627.3 | 285.1 | 117.01 | 68.83 | |
Revenue Growth | 49.44% | 64.02% | 120.03% | 143.66% | 70.00% | -8.23% |
Cost of Revenue | 584.4 | 408.1 | 234.6 | 144.2 | 65.36 | - |
Gross Profit | 774.1 | 620.8 | 392.7 | 140.9 | 51.64 | 68.83 |
Selling, General & Admin | 357.5 | 341.6 | 284.3 | 201 | 174.05 | 149.5 |
Research & Development | 378.3 | 414.7 | 413.5 | 382.2 | 335.65 | 313.35 |
Other Operating Expenses | 1 | 1 | - | 85.8 | - | - |
Operating Expenses | 736.8 | 757.3 | 697.8 | 669 | 509.7 | 462.85 |
Operating Income | 37.3 | -136.5 | -305.1 | -528.1 | -458.05 | -394.02 |
Interest Expense | -18.2 | -21.4 | -21.6 | -21.8 | -10.8 | -0.9 |
Interest & Investment Income | 29.2 | 40.1 | 61.2 | 54.5 | 8.18 | 0.97 |
Currency Exchange Gain (Loss) | -13.8 | -168.8 | 109.3 | -28.2 | -9.88 | - |
Other Non Operating Income (Expenses) | -0.1 | 4 | 2.5 | 3.4 | 24.22 | -12.27 |
EBT Excluding Unusual Items | 34.4 | -282.6 | -153.7 | -520.2 | -446.33 | -406.22 |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.6 | - |
Gain (Loss) on Sale of Assets | - | - | - | - | - | -0.97 |
Asset Writedown | -2.2 | - | -4.4 | - | - | - |
Pretax Income | 32.2 | -282.6 | -158.1 | -520.2 | -445.72 | -407.2 |
Income Tax Expense | 32.4 | 14.2 | 18.9 | -1.9 | 0.63 | -3.61 |
Net Income | -0.2 | -296.8 | -177 | -518.3 | -446.35 | -403.58 |
Net Income to Common | -0.2 | -296.8 | -177 | -518.3 | -446.35 | -403.58 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 188 | 184 | 183 | 176 | 159 | 141 |
Shares Outstanding (Diluted) | 188 | 184 | 183 | 176 | 159 | 141 |
Shares Change | 1.97% | 0.80% | 3.84% | 10.71% | 12.91% | 19.21% |
EPS (Basic) | -0.00 | -1.61 | -0.97 | -2.94 | -2.81 | -2.87 |
EPS (Diluted) | -0.01 | -1.62 | -0.97 | -2.94 | -2.81 | -2.87 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -187.1 | -128.8 | -158.1 | -413.4 | -222.21 | -240.66 |
Free Cash Flow Per Share | -1.00 | -0.70 | -0.86 | -2.35 | -1.40 | -1.71 |
Gross Margin | 56.98% | 60.34% | 62.60% | 49.42% | 44.14% | 100.00% |
Operating Margin | 2.75% | -13.27% | -48.64% | -185.23% | -391.48% | -572.49% |
Profit Margin | -0.01% | -28.85% | -28.22% | -181.80% | -381.48% | -586.38% |
Free Cash Flow Margin | -13.77% | -12.52% | -25.20% | -145.00% | -189.91% | -349.67% |
EBITDA | 50.1 | -127.1 | -294.4 | -517.4 | -445.41 | -385.88 |
EBITDA Margin | 3.69% | -12.35% | -46.93% | -181.48% | - | - |
D&A For EBITDA | 12.8 | 9.4 | 10.7 | 10.7 | 12.65 | 8.14 |
EBIT | 37.3 | -136.5 | -305.1 | -528.1 | -458.05 | -394.02 |
EBIT Margin | 2.75% | -13.27% | -48.64% | -185.23% | - | - |
Effective Tax Rate | 100.62% | - | - | - | - | - |
Revenue as Reported | 1,359 | 1,029 | 627.3 | 285.1 | 117.01 | 68.83 |